Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practice.
暂无分享,去创建一个
D. D. Giuseppe | B. Gudbjornsson | F. Iannone | L. Kuusalo | B. Glintborg | M. Hetland | T. Olofsson | G. Grondal | Ž. Rotar | S. Provan | K. P. Pirkmajer | M. Nissen | B. Michelsen | K. Fagerli | K. Laas | L. Midtbøll Ørnbjerg | S. N. Christiansen | Simon Horskjær Rasmussen | J. Vencovský | G. J. Macfarlane | A. G. Loft | Isabel Castrejón | M. Østergaard | R. Caporali | Dan C Nordström | M. Bernardes | L. Otero-Varela | Marion Pons | Jana Baranová | Gareth T Jones | Sigrid Vorobjov | M. V. D. van de Sande | Irene van der Horst-Bruinsma
[1] R. Landewé,et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update , 2022, Annals of the Rheumatic Diseases.
[2] R. Ramonda,et al. Secukinumab Drug Survival in Psoriasis and Psoriatic Arthritis Patients: A 24-Month Real-Life Study , 2022, Dermatology.
[3] A. Bergamini,et al. Effectiveness and safety of secukinumab in axial spondyloarthritis: a 24-month prospective, multicenter real-life study , 2022, Therapeutic advances in musculoskeletal disease.
[4] M. Dougados,et al. The ASAS-OMERACT core domain set for axial spondyloarthritis. , 2021, Seminars in arthritis and rheumatism.
[5] H. Mann,et al. Real‐World Six‐ and Twelve‐Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries , 2021, Arthritis care & research.
[6] V. Strand,et al. Secukinumab and Sustained Reduction in Fatigue in Patients With Ankylosing Spondylitis: Long‐Term Results of Two Phase III Randomized Controlled Trials , 2020, Arthritis care & research.
[7] G. Macfarlane,et al. Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration , 2020, RMD open.
[8] J. Primdahl,et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update , 2020, Annals of the Rheumatic Diseases.
[9] Claudia Fabiani,et al. Long-Term Effectiveness of Secukinumab in Patients with Axial Spondyloarthritis , 2020, Mediators of inflammation.
[10] R. Sengupta,et al. Real-world experience of secukinumab treatment for ankylosing spondylitis at the Royal National Hospital for Rheumatic Diseases, Bath , 2020, Clinical Rheumatology.
[11] J. P. Pinto Tasende,et al. Secukinumab as Biological Treatment for Psoriatic Arthritis in Real Clinical Practice. , 2019, Reumatologia clinica.
[12] V. Strand,et al. Secukinumab provides rapid and persistent relief in pain and fatigue symptoms in patients with ankylosing spondylitis irrespective of baseline C-reactive protein levels or prior tumour necrosis factor inhibitor therapy: 2-year data from the MEASURE 2 study. , 2019, Clinical and experimental rheumatology.
[13] P. Tugwell,et al. OMERACT Filter 2.1: Elaboration of the Conceptual Framework for Outcome Measurement in Health Intervention Studies , 2019, The Journal of Rheumatology.
[14] V. Strand,et al. Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study , 2018, Arthritis Research & Therapy.
[15] D. M. van der Heijde,et al. Health-related quality of life in patients with psoriatic and rheumatoid arthritis: data from the prospective multicentre NOR-DMARD study compared with Norwegian general population controls , 2018, Annals of the rheumatic diseases.
[16] H. Marzo-Ortega,et al. Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2 , 2017, RMD Open.
[17] J. Sieper,et al. Axial spondyloarthritis , 2017, The Lancet.
[18] S. Gaffen,et al. IL-17 Signaling: The Yin and the Yang. , 2017, Trends in immunology.
[19] M. Dougados,et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis , 2017, Annals of the rheumatic diseases.
[20] B. Shea,et al. International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials , 2016, Annals of the rheumatic diseases.
[21] M. Hiligsmann,et al. Which aspects of health are most important for patients with spondyloarthritis? A Best Worst Scaling based on the ASAS Health Index. , 2016, Rheumatology.
[22] V. Strand,et al. Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1) , 2016, Annals of the rheumatic diseases.
[23] M. D. de Wit,et al. Systematic literature review of domains assessed in psoriatic arthritis to inform the update of the psoriatic arthritis core domain set , 2016, RMD Open.
[24] M Cutolo,et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update , 2015, Annals of the rheumatic diseases.
[25] I. Olivieri,et al. Quality of life and unmet needs in patients with inflammatory arthropathies: results from the multicentre, observational RAPSODIA study. , 2015, Rheumatology.
[26] E. Kilic,et al. Relationship Between Psychiatric Status, Self-Reported Outcome Measures, and Clinical Parameters in Axial Spondyloarthritis , 2014, Medicine.
[27] P. Tugwell,et al. Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0. , 2014, Journal of clinical epidemiology.
[28] A. Loft,et al. Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry. , 2013, Arthritis and rheumatism.
[29] A. Loft,et al. Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry , 2012, Annals of the rheumatic diseases.
[30] P. Tugwell,et al. American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials , 2011, Annals of the rheumatic diseases.
[31] W. Dixon,et al. EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology , 2010, Annals of the rheumatic diseases.
[32] M. Østergaard,et al. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry , 2010, Annals of the rheumatic diseases.
[33] M. Dougados,et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection , 2009, Annals of the rheumatic diseases.
[34] L. Coates,et al. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment , 2009, Annals of the rheumatic diseases.
[35] Dafna Gladman,et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. , 2006, Arthritis and rheumatism.
[36] P. Geborek,et al. The LUNDEX, a new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden. , 2006, Arthritis and rheumatism.
[37] J J Anderson,et al. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. , 2001, Arthritis and rheumatism.
[38] A. Cats,et al. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. , 1984, Arthritis and rheumatism.
[39] D. Gladman,et al. Psoriatic Arthritis. , 2017, The New England journal of medicine.